Science AI Journal
Medicine · Research topic

Open research questions in Gout, Hyperuricemia, Uric Acid

52 unresolved questions extracted from the limitations and future-work sections of 248 Gout, Hyperuricemia, Uric Acid papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The crystal arthropathies gout and calcium pyrophosphate deposition (CPPD) disease represent a significant subset of rheumatic and musculoskeletal diseases, yet their overlap with common entities such as osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PsA) remains underrecognized.

    Overlap of Gout and Calcium Pyrophosphate Deposition with Osteoarthritis, Rheumatoid Arthritis, and Psoriatic Arthritis: Epidemiology, Clinical-Radiological Profiles, Outcomes, and Management · 2026 · DOI

  • Pre-discharge SUA, but not admission SUA, is independently associated with long-term adverse outcomes in acute HFpEF patients. Dynamic in-hospital SUA trajectories (especially H-H and N-H) show stronger associations with MACE than single measure- ments, suggesting added prognostic value. These hypothesis-gener- ating findings indicate that monitoring SUA dynamics may aid risk stratification. Future prospective studies should validate these asso- ciations and test whether nutritional or urate-lowering interven- tions improve outcomes in high-risk trajectory groups.

    Leveraging dynamic serum uric acid trajectories for risk stratification in hospitalized HFpEF patients · 2026 · DOI

  • Several limitations of this study should be acknowledged. First, this is an observational study; despite rigorous multivariable adjustment and sensitivity analyses, causality cannot be inferred. All findings and interpreted hypothesis-generating. associational should be as Second, our trajectory classification was based on only two SUA measurements (admission and pre-discharge). This simplification may not fully capture complex in-hospital fluctuations (e.g., multiple peaks or nadirs) and may miss dynamic patterns that require three or more serial measurements. Therefore, our trajectory groups represent a pragmatic approximation rather than a true longitudinal characterization. Third, the optimal SUA cut-off for MACE prediction (5.6 mg/dL) was derived from this cohort and has not been externally validated. Its generalizability to other populations or settings is uncertain. We therefore suggest that SUA should be used in combination with other clinical markers (e.g., BNP, eGFR, age) for risk stratification, rather than as a standalone test.

    Leveraging dynamic serum uric acid trajectories for risk stratification in hospitalized HFpEF patients · 2026 · DOI

  • Building on the hypothesis generated above, this section reviews current evidence on nutritional strategies that may influence SUA dynamics and HFpEF prognosis. To translate our associational find- ings into a hypothesis-generating framework, we propose a risk- stratified nutritional pathway for HFpEF patients identified with adverse SUA trajectories (N-H and H-H groups). This pathway can be conceptualized as three sequential steps: identification at dis- charge, targeted medical nutrition therapy (MNT), and longitudinal monitoring. First, at discharge, SUA trajectories should be calculated from admission and pre-discharge measurements, and patients classified into N-H or H-H groups should be flagged for intensified nutritional follow-up. Second, for these high-risk patients, individualized MNT should target the three main metabolic drivers of SUA elevation: purine intake, fructose consumption, and insulin resistance (36). Dietary strategies include: (i) a low-purine diet (limiting red/organ meats, certain seafood, and meat broths), supported by a 2025 systematic review of 8 studies (47,879 participants) showing that dietary modi- fication lowers SUA (37); (ii) fructose restriction (avoiding sugar- sweetened beverages and processed foods with high-fructose corn syrup), as specifically recommended by the same review (37); (iii) a plant-based or DASH diet (emphasizing fruits, vegetables, legumes, whole grains, and low-fat dairy), with randomized trial evidence demonstrating a mean SUA reduction of 0.25 mg/dL overall (and 0.73 mg/dL in those with baseline SUA ≥ 8 mg/dL) within 30 days, an effect sustained at 90 days (38, 39); and (iv) adequate hydration (daily water intake >2000 mL, approximately 8–10 cups, unless contraindi- cated), based on 2025 expert consensus for high-risk hyperurice- mia (40). Third, longitudinal monitoring should include a follow-up visit at 4–6 weeks to reassess SUA, eGFR, BNP, and dietary adherence (18). If SUA reduction from the pre-discharge level is <10%, rein- forced nutritional counseling and more frequent monitoring (every 4 weeks) should be considered (41). Thereafter, patients should be followed every 3–6 months alongside routine HF care (42). When optimal nutritional intervention fails to achieve the guide- line-recommended SUA target of <6 mg/dL (18, 40), adjunctive phar- macotherapy may be considered. In HFpEF, SGLT-2i is the preferred option (7, 19, 34). Conventional xanthine oxidase inhibitors (allopu- rinol or febuxostat) also lower SUA but have shown inconsistent asso- ciations with outcomes in HF (9, 11, 17). Therefore, if used, they should be part of a multifactorial management plan and prescribed with caution. This hypothesis-generating pathway provides a translational basis for future interventional studies testing whether SUA-guided nutri- tional management improves clinical outcomes in HFpEF.

    Leveraging dynamic serum uric acid trajectories for risk stratification in hospitalized HFpEF patients · 2026 · DOI

  • The specific bioactive flavonoid aglycones and triterpenoid saponins responsible for xanthine oxidase inhibition versus renal hemodynamic effects have not been isolated, quantified, or independently validated in the standardized S. polyanthum extract. Chromatographic characterization and dose-response studies of individual polyphenolic compounds, hydrolyzable tannins, and essential oil components are needed to establish which botanical constituents mediate the observed urate-lowering effects.

    Short-Term Clinical Effects of Standardized Syzygium polyanthum (Bay Leaf) Tea Infusion on Serum Uric Acid Modulation in Hyperuricemia: A Pilot Trial in Primary Care · 2026 · DOI

  • Sex-based physiological differences in urate handling and diagnostic thresholds are mentioned (female patients have inherently lower diagnostic thresholds and physiological tolerance for urate than males), but the pilot trial does not provide stratified analysis of serum uric acid reduction efficacy, renal clearance rates, or adverse outcome risks stratified by biological sex in S. polyanthum-treated hyperuricemia patients.

    Short-Term Clinical Effects of Standardized Syzygium polyanthum (Bay Leaf) Tea Infusion on Serum Uric Acid Modulation in Hyperuricemia: A Pilot Trial in Primary Care · 2026 · DOI

  • Integration of the standardized botanical tea intervention into Indonesian primary care frameworks (specifically the Integrated Guidance Post for Non-Communicable Diseases) and village-level healthcare facilitator distribution programs requires implementation studies assessing feasibility, adherence, cost-effectiveness, and clinical outcomes when deployed at scale across rural and urban Southeast Asian populations.

    Short-Term Clinical Effects of Standardized Syzygium polyanthum (Bay Leaf) Tea Infusion on Serum Uric Acid Modulation in Hyperuricemia: A Pilot Trial in Primary Care · 2026 · DOI

  • Long-term rheumatological safety and sustained efficacy of the standardized S. polyanthum formulation remain unestablished beyond the seven-day intervention period. Prospective longitudinal trials tracking serum uric acid normalization, complete biochemical homeostasis maintenance, and optimal long-term rheumatological safety endpoints over months to years are necessary to validate clinical utility in chronic hyperuricemia management.

    Short-Term Clinical Effects of Standardized Syzygium polyanthum (Bay Leaf) Tea Infusion on Serum Uric Acid Modulation in Hyperuricemia: A Pilot Trial in Primary Care · 2026 · DOI

  • The proposed dual-action mechanism of S. polyanthum (xanthine oxidase inhibition via flavonoid competitive binding combined with renal hemodynamic modulation via eugenol-induced vasorelaxation) has been characterized only through in vitro pharmacological models and mechanistic theory. Direct in vivo measurement of both renal afferent arteriole vasorelaxation and glomerular filtration rate modulation in hyperuricemic subjects receiving the standardized botanical extract is required to validate this integrated multi-pathway physiological response.

    Short-Term Clinical Effects of Standardized Syzygium polyanthum (Bay Leaf) Tea Infusion on Serum Uric Acid Modulation in Hyperuricemia: A Pilot Trial in Primary Care · 2026 · DOI

  • The seven-day standardized S. polyanthum tea intervention achieved a median serum uric acid reduction to 6.9 mg/dL, which remains above the critical 6.0 mg/dL therapeutic threshold required to prevent monosodium urate crystal nucleation and tissue deposition. Extended intervention duration studies are needed to determine whether prolonged S. polyanthum administration can achieve sustained urate levels below 6.0 mg/dL in hyperuricemia patients.

    Short-Term Clinical Effects of Standardized Syzygium polyanthum (Bay Leaf) Tea Infusion on Serum Uric Acid Modulation in Hyperuricemia: A Pilot Trial in Primary Care · 2026 · DOI

  • Ethics statement This study has several limitations. First, given the retrospective observational design, residual confounding cannot be fully eliminated and causal inference is not possible. Second, our inclusion/exclusion criteria may have introduced selection bias and limited external validity because we excluded women with chronic hypertension, and other comorbidities that commonly coexist with advanced maternal age; therefore, the findings are most applicable to women with advanced maternal age who had singleton spontaneous pregnancies and were free of these major comorbidities at baseline. Third, to reduce reverse causality, SUA and sCr were measured at the initial antenatal visit (median 12.0 weeks; IQR: 10.1–13.8 weeks) and no SUA/sCr measurements occurred after a preeclampsia diagnosis; however, subclinical pathophysiological changes may precede clinical diagnosis, so reverse causality cannot be completely excluded. Finally, several important confounders were unavailable or could not be reliably ascertained, including pre-pregnancy BMI, smoking, socioeconomic indicators, diet, physical activity, and exposure during some pregnancy (notably aspirin prophylaxis, antihypertensive agents, urate-lowering therapy, and other drugs affecting renal function or uric acid metabolism) was not systematically recorded and could not be adjusted for. conditions. Medication chronic The studies involving humans were approved by Changde Hospital, Xiangya School of Medicine, Central South University (The first people’s hospital of Changde city)(approval number: 2024-190-01). The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from primarily isolated as part of your previous study for which ethical approval was obtained. Written informed consent for participation was not required legal guardians/next of kin in accordance with the national legislation and institutional requirements.

    Association between the serum uric acid-to-creatinine ratio index and the risk of preeclampsia in advanced maternal age pregnant women: a retrospective cohort study · 2026 · DOI

  • Future work should (1) develop and externally validate prediction models that integrate SUA/sCr with blood pressure, renal markers, and other clinical parameters in women of advanced maternal age; (2) establish prospective cohorts with repeated measurements across gestation to better define temporal patterns; and (3) assess whether modifiable factors or interventions that influence SUA/sCr are associated with reduced preeclampsia risk, with standardized capture and adjustment for key medication exposures (including aspirin prophylaxis and antihypertensive therapy).

    Association between the serum uric acid-to-creatinine ratio index and the risk of preeclampsia in advanced maternal age pregnant women: a retrospective cohort study · 2026 · DOI

  • The crosslinking density of GelMA may affect the enzymolysis rate, and the relationship between the crosslinking degree (such as 10%, 20%, 30%) and the enzyme activity retention rate needs to be systematically studied to optimize the carrier design.

    Construction of Oral Urate Oxidase Delivery System Based on Sodium Alginate/GelMA Composite System and Its Effect on Lowering Uric Acid · 2026 · DOI

  • The synergistic effect of aprotinin and GelMA immobilization can be further quantified by controlled experiments, such as the preparation of microspheres containing only GelMA-UOX.

    Construction of Oral Urate Oxidase Delivery System Based on Sodium Alginate/GelMA Composite System and Its Effect on Lowering Uric Acid · 2026 · DOI

  • The study did not independently evaluate the protective effect of aprotinin-free GelMA microspheres on UOX, so it is not possible to fully distinguish the independent contribution of aprotinin inhibition from GelMA immobilization.

    Construction of Oral Urate Oxidase Delivery System Based on Sodium Alginate/GelMA Composite System and Its Effect on Lowering Uric Acid · 2026 · DOI

  • There is currently limited data on uraemic syndrome in horses with ARF, however, there are some case reports such as the report from Fernandes and Robin (2025) and Bouchard et al.

    Uraemic syndrome following acute renal failure in horses · 2025 · DOI

  • Gene–nutrient interaction studies have demonstrated that IL-1β-related variants may modify metabolic responses to specific fatty acids, suggesting the need for further investigation of these interactions in gout patients.

    IL-1 cluster gene polymorphisms in Turkish patients with gout and their association with ınflammatory markers: a cross-sectional genetic study · 2025 · DOI

  • The relationship between serum uric acid concentration and other critical heart failure parameters (brain natriuretic peptide levels, cardiac output, pulmonary capillary wedge pressure, exercise tolerance) is not examined. Correlation analysis between uric acid and comprehensive hemodynamic/functional parameters in NYHA III-IV patients would clarify the specificity of the uric acid-ejection fraction association.

    The effect of serum uric acid concentration on the severity of chronic congestive heart failure · 2022 · DOI

  • No specific threshold or cut-off value for serum uric acid is identified that discriminates between NYHA III and NYHA IV severity or predicts clinically significant ejection fraction decline. Receiver operating characteristic (ROC) curve analysis with determination of optimal uric acid cut-off values for predicting NYHA classification progression and ejection fraction thresholds in heart failure patients is absent.

    The effect of serum uric acid concentration on the severity of chronic congestive heart failure · 2022 · DOI

  • The study population and demographic characteristics (age range, comorbidities, race/ethnicity, geographic origin) are not described in the provided excerpt. Validation of the serum uric acid-heart failure severity relationship across diverse populations (African, Asian, Caucasian cohorts) and different geographic settings is required to establish generalizability beyond the original Kufa University cohort.

    The effect of serum uric acid concentration on the severity of chronic congestive heart failure · 2022 · DOI

  • The paper references multiple mechanisms (oxidative stress, renin-angiotensin system activation, endothelial dysfunction) through which uric acid may worsen heart failure, but does not investigate which pathway is predominant in chronic congestive heart failure or whether pathway dominance varies by NYHA stage. Mechanistic studies measuring oxidative stress markers, endothelial function biomarkers, and renin-angiotensin system activity across NYHA I-IV patients with elevated uric acid are needed.

    The effect of serum uric acid concentration on the severity of chronic congestive heart failure · 2022 · DOI

  • The study establishes an association between serum uric acid concentration and congestive heart failure severity (NYHA III-IV) and reduced left ventricular ejection fraction, but does not clarify whether this relationship is causal or merely correlational. Prospective intervention studies with urate-lowering therapy (allopurinol, febuxostat) in heart failure populations are needed to determine if reducing serum uric acid improves ejection fraction and NYHA classification.

    The effect of serum uric acid concentration on the severity of chronic congestive heart failure · 2022 · DOI

  • The normalization of uric acid levels against the background of allopurinol was observed only in 20% of cases, possibly associated with insufficiently selected drug doses that do not provide the necessary hypouricemic effect.

    Characteristics of clinical manifestations of gout in the elderly people · 2022 · DOI

  • It was not possible to objectively assess the characteristics of the course of gout in women since only 3 women presented with onset of gout in the interphalangeal joints of the hands, despite 39 women total participating in the study.

    Characteristics of clinical manifestations of gout in the elderly people · 2022 · DOI

  • Chronic asymptomatic hyperuratemia (HUA), gout paroxysm in patients with chronic hyperuratemia (HU) and normouricemic attacks of gouty arthritis are well known, but poorly understood.

    Novelties in gout · 2013 · DOI

Most-cited papers in Gout, Hyperuricemia, Uric Acid

Most recent work

Find a gap in your own Gout, Hyperuricemia, Uric Acid sub-topic

This page shows what the Gout, Hyperuricemia, Uric Acid literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
52 open questions have been extracted from the limitations and future-work passages of 248 Gout, Hyperuricemia, Uric Acid papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.